January 2012 Blog Posts (38)

Vismodegib - First Medicine for Adults with Advanced Basal Cell Carcinoma (BCC) Approved by FDA

The U.S. Food and Drug Administration (FDA) has approved vismodegib (Erivedge™, Roche/Genentech), the first medicine for adults with a type of skin cancer, called advanced or metastatic basal cell carcinoma or BCC, that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. The new drug is a first-in-class Hedgehog Pathway…

Continue

Added by Peter Hofland, PhD on January 30, 2012 at 10:30am — No Comments

Axitinib Approved to Treat Patients With a Type of Advanced Kidney Cancer

Earlier today, the U.S. Food and Drug Administration (FDA) announced that the agency has approved axitinib (Inlyta®, Pfizer Inc) to treat patients with advanced or metastatic renal cell carcinoma (mRCC) who have not responded to another drug for this type of cancer. Axitinib helps keep the cancer from progressing.…



Continue

Added by Peter Hofland, PhD on January 27, 2012 at 11:00am — No Comments

New Data Finds Racial and Ethnic Disparities in US Cancer Screening: Rates Lower Among Asian and Hispanic Americans

A new study finds the percentage of U.S. citizens screened for cancer remains below national targets, with significant disparities among racial and ethnic populations. The data comes from the first federal study to identify cancer screening disparities among Asian and Hispanic groups. The report by the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), part of the National Institutes of…

Continue

Added by Peter Hofland, PhD on January 26, 2012 at 5:30pm — No Comments

Routine PET/CT Detects Local Recurrences - May Improve Outcome of Subsequent Salvage Therapy

Routine use of positron emission tomography/computed tomography (PET/CT) scans in head and neck cancer patient follow-up can detect local recurrences before they become clinically apparent and may improve the outcome of subsequent salvage therapy, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, held from January 26-28, 2012 in the Biltmore, Phoenix, Arizona.



Extracranial head-and-neck carcinomas constitute of less…

Continue

Added by Peter Hofland, PhD on January 26, 2012 at 4:00pm — No Comments

Patients Receiving Radiation with IMRT for Head and Neck Cancer Report Better Quality of Life Post-treatment

Patients treated with Intensity Modulated Radiation Therapy or IMRT for head and neck cancer report an increasingly better quality of life post-treatment when compared to patients receiving other forms of radiation therapy, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, held from January 26-28, 2012 in the Biltmore, Phoenix, Arizona.



Intensity modulated radiation therapy, or IMRT, is a highly specialized form of…

Continue

Added by Peter Hofland, PhD on January 26, 2012 at 3:00pm — No Comments

Danish Fast Track Cancer Care Program Could Reduce Risk of Recurrence and Lowers Cost to Government

A Danish national fast track system for cancer patients reduced the waiting time between a patient’s initial meeting with a health care provider and their first treatment by four weeks when comparing 2010 to 2002, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, held from January 26-28, 2012 in the Biltmore, Phoenix, Arizona.



Denmark’s health care system is state run. Health care services are funded by taxes with no…

Continue

Added by Peter Hofland, PhD on January 26, 2012 at 2:30pm — No Comments

Men More Prone Than Women to Develop HPV Related Head and Neck Cancer

Oral HPV infection is more common among men than women, explaining why men are more prone than women to develop an HPV related head and neck cancer, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, held from January 26-28, 2012 in the Biltmore, Phoenix, Arizona.



Human papillomavirus, or HPV, has recently been linked to some types of head and neck cancer that are becoming more prominent in the United States, mostly…

Continue

Added by Peter Hofland, PhD on January 26, 2012 at 11:30am — No Comments

Standard Treatment of Head and Neck Squamous Cell Carcinoma Less Effective in HIV-positive Patients



Radiation therapy with or without chemotherapy is less effective for patients with HIV when compared to the recurrence and overall survival rates in patients who do not have HIV, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, held from January 26-28, 2012 in the Biltmore, Phoenix, Arizona.



Treating head and neck cancer in HIV-positive patients is a challenge for oncologists. Because of the advancements in… Continue

Added by Peter Hofland, PhD on January 26, 2012 at 11:30am — No Comments

Adjusting Dose of Erlotinib According to Patient’s Smoking Habit Effective as First Treatment for Head and Neck Cancer

Head and neck cancers respond well to the anti-cancer drug erlotinib (Tarceva®, Genentech) when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, held from January 26-28, 2012 in the Biltmore, Phoenix, Arizona.



Erlotinib is an oral anti-cancer drug that can slow a…

Continue

Added by Peter Hofland, PhD on January 26, 2012 at 11:00am — No Comments

New Pathway Can Overcome Glioblastoma Resistance - Leading to New Therapeutic Target

Glioblastoma, a lethal brain cancer, is one of the most resistant to available therapies and patients typically live approximately 15 months. Previous research has focused on the activation of the apoptosis, or cell death, pathway using therapeutic agents such as tumor necrosis factor-related apoptosis-inducing ligand (TRAIL); however, the vast majority of these experiments have been stymied by resistance.



“Scientists in this field have been hoping to treat this…

Continue

Added by Peter Hofland, PhD on January 24, 2012 at 7:30pm — No Comments

Therapeutic Cancer Vaccine IMA910 Shows Positive Phase II Results in Patients With Advanced Colorectal Cancer (mCRC)

Results from a Phase II clinical trial with IMA910 in patients with advanced colorectal cell carcinoma (CRC), which were presented at the Gastrointestinal Cancers Symposium of the 2012 American Society of Clinical Oncology (ASCO) in San Francisco showed positive results.



IMA910, developed by German clinical-stage biopharmaceutical company immatics biotechnologies GmbH, is therapeutic cancer vaccine…

Continue

Added by Peter Hofland, PhD on January 24, 2012 at 4:00pm — No Comments

Detecting Early Stage Pancreatic Cancer: New Test Opens Possibility for Personalized Treatment

Results of a study presented at ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, CA, USA show that a test using a monoclonal antibody to detect a cancer marker, the PAM4-protein, in the blood correctly identified nearly two thirds of patients with early stage pancreatic cancer.



When combined with CA19-9, another tumor marker that is commonly used to monitor the course of the…

Continue

Added by Peter Hofland, PhD on January 20, 2012 at 7:30pm — No Comments

Prognostic Factors for Rare Neuroendocrine Tumors (NET) Suggests Everolimus May Be More Beneficial Than Previously Shown

Researchers re-analyzing the results of a large phase III study of patients with advanced neuroendocrine tumors (NET) found that certain factors, such as bone metastases, having NETs that originate in the lung, and elevated levels of the blood biomarker chromogranin A predict which individuals are at greatest risk for neuroendocrine tumor progression and are more likely to need active therapy. The results of the study were presented at the 9th Annual Gastrointestinal Cancers…

Continue

Added by Peter Hofland, PhD on January 20, 2012 at 7:30pm — No Comments

International Colon cancer Organizations Join Forces to Combat Disease on a Global Level

The launch of the Global Colon Cancer Alliance (GCCA) was announced today at the ASCO Gastrointestinal Cancers Symposium in San Francisco, California. The newly formed alliance unites two leading advocacy organizations: the Colon Cancer Alliance, a patient advocacy organization based in the United States that provides hope and support to patients and their families, while saving lives through screening, access, awareness, advocacy…

Continue

Added by Editorial Team on January 19, 2012 at 9:30pm — No Comments

New Biomarkers May Help Improve Early Detection of Esophageal Cancer

A study presented at the ninth annual Gastrointestinal Cancers Symposium being held January 19-21, 2012, at The Moscone West Building in San Francisco, CA, USA, has identified new biomarkers that could eventually improve early detection of esophageal cancer in patients with Barrett’s esophagus (BE) or Barrett's Syndrome. BE refers to a metaplasia or abnormal change in the cells of the inferior portion of the esophagus and is known to significantly increases esophageal cancer…

Continue

Added by Peter Hofland, PhD on January 19, 2012 at 7:30pm — No Comments

Regorafenib Shows Statistically Significant Improvement in OS in Patients with mCRC Refractory to Standard Approved Therapies

The latest data on the investigational drug regorafenib (BAY 73-4506)from the Phase III CORRECT trial(Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) were presented at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI), in San Francisco, CA.



Regorafenib (BAY 73-4506) is an an investigational oral multi-kinase inhibitor developed by Bayer which targets angiogenic,…

Continue

Added by Peter Hofland, PhD on January 18, 2012 at 9:30am — No Comments

Incidence of Brain Tumours is Not Increasing in Nordic Countries

The incidence of glioma - the most common form of brain tumour - is not increasing in the Nordic countries, contradicting the claim that cell phone use is a cause of the disease. This according to a new study from Karolinska Institutet published in the scientific journal Epidemiology. The analyses…

Continue

Added by Peter Hofland, PhD on January 17, 2012 at 6:30pm — No Comments

Data From 15 Million Cases in 60 Countries Shows Men at Higher Risk for 32 out of 35 Cancers

While it is well established that men get cancer more than women, and sometimes at considerably higher rates, few scientists have examined why. In an article published this month in the online version of the European Journal of Epidemiology, a group of American and Swedish researchers, including the Cancer Prevention Institute of California (CPIC),…

Continue

Added by Peter Hofland, PhD on January 17, 2012 at 12:30pm — No Comments

Cancer Drug Shortage: There is Help

Is there a cancer drug shortage? If you've listened to the news lately, you've probably heard that there is indeed a drug shortage. Hospitals and pharmacies across the United States, Canada, Europe and Australia are running short of important drugs used to treat several forms of cancer and serious infections after a manufacturer decide to temporarily halt production. They are now bracing for possible…

Continue

Added by Pam Brammann, R.N. on January 12, 2012 at 3:30pm — 1 Comment

'Liquid Biopsy' Approved for Breast Cancer Patients in China

The China State Food & Drug Administration (SFDA) has approved the CellSearch® circulating tumor cell (CTC) test (Veridex) as an in vitro diagnostic for women with metastatic breast cancer. This makes CellSearch® the first and only approved CTC test for cancer patients in China, which is…

Continue

Added by Editorial Team on January 12, 2012 at 3:00pm — No Comments

Monthly Archives

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

Register for free to view all the Onco'Zine - The International Oncology Network content:

ADVERTISEMENT/MEDIA PARTNER

Onco'Zine is present here

Bookmark / Share

CONNECT WITH US AND

JOIN THE CONVERSATION


© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+